MEDACTA Group MOVE.SW
SwitzerlandHealthcare · Medical DevicesSIX Swiss Exchange · CHF
160.46 CHF (+40.5%)
6 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers7.04 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
MEDACTA Group is a Swiss medical devices company that designs, manufactures, and markets products for orthopedic surgery, mainly implants and solutions for hip and knee arthroplasty.
Listed on SIX Swiss Exchange · Symbol MOVE.SW · SWX: MOVE · Currency CHF
Key points
from its scores- ✕Poor share-price trend2.2
- ✕Weak growth3.4
- ✕Demanding valuation3.5
AI analysis
bottom line, main risk, context and newsHold in portfolio only for long-term investors who trust in the recovery of earnings growth; the current valuation offers no margin of safety.
MEDACTA Group shows solid financial health (6.9) with moderate leverage (ND/EBITDA of 1.67) and good liquidity (2.10), but its valuation is demanding (P/E 31.90) and earnings growth is very negative (-30.20%), which weighs on its attractiveness. Business quality is good (gross margin 65.51%, ROE 17.03%), but negative free cash flow conversion (-29.61%) and poor momentum (2.19) suggest caution.
The main risk is the 30.20% decline in earnings growth, which could indicate operational or market issues, and the negative free cash flow conversion (-29.61%), which limits investment capacity and shareholder returns.
Context and risks
MEDACTA Group, domiciled in Switzerland, operates in the medical devices sector, an area subject to continuous regulatory scrutiny and potential pricing pressures in major markets. Although Switzerland offers a solid institutional framework, exposure to global health regulation and product approval cycles introduces a specific risk not reflected in financial metrics.
Is MEDACTA Group stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 31.9 | 26.7 | +19% |
| EV / EBITDA | 16.0 | 14.5 | +10% |
| Price / book | 5.3 | 4.1 | +30% |
| Price / sales | 3.4 | 3.4 | +1% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 160.46 CHF, +40.5% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 31.9
- Forward P/E
- 21.5
- EV / EBITDA
- 16.0
- Price / book
- 5.3
- Price / sales
- 3.4
- Market cap
- 2.3B CHF
- Enterprise value
- 2.7B EUR
Profitability
- ROE
- 17.0%
- ROA
- 7.2%
- ROIC (approx.)
- 13.6%
- Gross margin
- 65.5%
- Operating margin
- 15.0%
- Net margin
- 10.9%
- Free cash flow
- −50.5M EUR
- FCF yield
- −2.1%
- Cash conversion
- −30%
Solvency
- Total debt
- 320.6M EUR
- Net debt
- 284.6M EUR
- Cash
- 36.0M EUR
- EBITDA
- 170.5M EUR
- Net debt / EBITDA
- 1.67
- Debt / equity
- 66.36
- Current ratio
- 2.10
- Quick ratio
- 0.74
Growth
- Revenue growth
- +7.0%
- Earnings growth
- −30.2%
- EPS (TTM)
- 3.58 CHF
- EPS (forward)
- 5.31 CHF
Dividend
- Dividend yield
- 1.0%
- Payout
- 30.6%
Risk and market
- Beta
- 1.01
- Analyst consensus
- none (6)
- Target price
- 160.46 CHF
- 52-week range
- 107.40 – 177.20
Recent news
All MOVE.SW news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about MEDACTA Group
Is MEDACTA Group stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 3.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 160.46 CHF, +40.5% versus the price. This is not investment advice.
What score does MEDACTA Group get on MeridIAn Screener?
It scores 4.8 out of 10, rank 1,785 of 2,130 (better than 16% of the companies analysed). Its strongest category is Financial health (6.9) and its weakest, Momentum (2.2). Analysis of 08/10/2026.
What is MEDACTA Group's P/E ratio?
Its P/E is 31.9: the share price equals 31.9 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 21.5.
How much is MEDACTA Group worth on the stock market?
Its market capitalisation is 2.3B CHF and its enterprise value, debt included, is 2.7B CHF.
How much debt does MEDACTA Group have?
Its net debt (debt minus cash) is 284.6M EUR. That is 1.67 times its EBITDA; the Healthcare median is 1.53.
Does MEDACTA Group pay a dividend?
Yes: its dividend yield is 0.96% and it pays out 31% of its earnings.
How has MEDACTA Group stock performed over the last year?
It has fallen 22.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 107.40 and 177.20 CHF. Past performance does not guarantee future results.
What do analysts think of MEDACTA Group?
6 analysts cover it; their average recommendation is “none” and their average target is 160.46 CHF (+40.5% versus the price). It is an estimate, not market data.